Zhejiang Jingxin Pharmaceutical Co Ltd. Stock Analysis 002020.SZ

Zhejiang Jingxin Pharmaceutical Co., Ltd. manufactures and sells pharmaceutical products for the treatment of central nervous system and cardiovascular disorders. The company is headquartered in Shaoxing, Zhejiang and currently employs 3,732 full-time employees. The company went IPO on 2004-07-15. The firm operates four segments. The Finished Drug business segment is engaged in the production and sales of preparations such as Kangfuxinye, Bacillus licheniformis Live Bacteria Capsules, Simvastatin Tablets, Rosuvastatin Calcium Tablets, Pivastatin Calcium Dispersible Tablets, and Sertraline Hydrochloride Tablets. The Active Pharmaceutical Ingredients (APIs) Business segment is engaged in the production and sale of quinolones, statins, and psychoneurotic APIs. The Medical Device Business segment is engaged in the research and development, production and sales of medical-specific displays, and provides full-process services from pre-sale research and development to after-sale maintenance, main products including customized medical display products and standardized medical display products. Other Business segment is engaged in real estate rental business.